IBI-80090

IBI-80090 is a preclinical-stage sustained-release formulation of the platinum-based chemotherapeutic agent carboplatin, developed by Icon Bioscience (now EyePoint Pharmaceuticals) for the treatment of retinoblastoma. The drug utilizes the proprietary Verisome drug delivery platform, which consists of a biodegradable, injectable liquid that forms a solid or semi-solid depot upon administration into the eye (typically via intravitreal injection). This technology is designed to provide controlled, long-term release of carboplatin directly to the tumor site, thereby maximizing therapeutic efficacy while minimizing the systemic toxicity and the need for frequent invasive procedures associated with conventional chemotherapy.

Other names

Verisome carboplatin